136 related articles for article (PubMed ID: 2317160)
21. [Effects of fibrinogen, fibrin and their degradation products on the behaviour of vascular smooth muscle cells].
Naito M
Nihon Ronen Igakkai Zasshi; 2000 Jun; 37(6):458-63. PubMed ID: 10998926
[TBL] [Abstract][Full Text] [Related]
22. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)).
Smith EB; Cochran S
Atherosclerosis; 1990 Oct; 84(2-3):173-81. PubMed ID: 2149268
[TBL] [Abstract][Full Text] [Related]
23. Fibrinogen, fibrin and the arterial wall.
Smith EB
Eur Heart J; 1995 Mar; 16 Suppl A():11-4; discussion 14-5. PubMed ID: 7796823
[TBL] [Abstract][Full Text] [Related]
24. The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition.
Ichikawa K; Nakagawa K; Hirano K; Sueishi K
Pathol Res Pract; 1996 Mar; 192(3):224-32. PubMed ID: 8739469
[TBL] [Abstract][Full Text] [Related]
25. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
Rozenfel'd MA; Leonova VB; Khavkina LS
Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
[TBL] [Abstract][Full Text] [Related]
26. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system.
Sasajima T; Takano Y; Hiraishi Y; Goh K; Inaba M; Azuma N; Sasajima Y; Yamazaki K; Yamamoto H
J Vasc Surg; 2000 Aug; 32(2):374-82. PubMed ID: 10917998
[TBL] [Abstract][Full Text] [Related]
27. Thrombosis in atherogenesis.
Kaplan KL; Bini A
Crit Rev Oncol Hematol; 1989; 9(4):305-18. PubMed ID: 2688680
[TBL] [Abstract][Full Text] [Related]
28. Plasmic degradation of fibrinogen Paris I.
Budzynski AZ; Marder VJ
J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the physicochemical properties of fragment D derivatives of fibrinogen and fragment D-D of cross-linked fibrin.
Marder VJ; Budzynski AZ; Barlow GH
Biochim Biophys Acta; 1976 Mar; 427(1):1-14. PubMed ID: 130927
[TBL] [Abstract][Full Text] [Related]
30. Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease.
Sun S; Karsdal MA; Mortensen JH; Luo Y; Kjeldsen J; Krag A; Jensen MD; Bay-Jensen AC; Manon-Jensen T
J Gastrointestin Liver Dis; 2019 Jun; 28():175-182. PubMed ID: 31204415
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolysis and plasminogen concentration in aortic intima in relation to death following myocardial infarction.
Smith EB; Ashall C
Atherosclerosis; 1985 May; 55(2):171-86. PubMed ID: 4004989
[TBL] [Abstract][Full Text] [Related]
33. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency.
Okajima K; Kohno I; Soe G; Okabe H; Takatsuki K; Binder BR
Am J Hematol; 1994 Jan; 45(1):16-24. PubMed ID: 8250008
[TBL] [Abstract][Full Text] [Related]
34. The course and prerequisites of Lys-plasminogen formation during fibrinolysis.
Suenson E; Thorsen S
Biochemistry; 1988 Apr; 27(7):2435-43. PubMed ID: 3382632
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
Khavkina LS; Rozenfeld MA; Leonova VB
Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
[TBL] [Abstract][Full Text] [Related]
36. [Atherogenic modifications of low density lipoproteins during fibrin formation and fibrinolysis].
Chulkova TM
Vopr Med Khim; 1989; 35(2):72-5. PubMed ID: 2741416
[TBL] [Abstract][Full Text] [Related]
37. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
[TBL] [Abstract][Full Text] [Related]
38. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
Lane DA; Preston FE; VanRoss ME; Kakkar VV
Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of a new fibrinogen/fibrin degradation products(FDP) test using plasma samples for the diagnosis of fibrinogenolysis and fibrinolysis].
Imoto K; Yasumuro Y; Taki M; Suzuki N; Tanabe H; Ichikawa Y
Rinsho Byori; 2001 Mar; 49(3):283-9. PubMed ID: 11307330
[TBL] [Abstract][Full Text] [Related]
40. Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma).
Falanga V; Kruskal JB; Franks JJ
J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):771-5. PubMed ID: 1802898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
